Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belatacept Conversion in Adolescent Renal Allograft Recipients
NCT04877288Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2021
- Primary completion
- Dec 2032
- Modality
- Fc-Fusion Proteins
- Countries
- 10
01
Overview
A Phase 3 trial of belatacept in kidney transplant rejection, sponsored by Bristol Myers Squibb. Started Jul 2021; status: recruiting.
02
Drugs
belatacept
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT04877288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04877288.